Drug Target Review2025-01-28T08:00:44
Cancer Research UK, Cytovation, and the Norwegian Cancer Society have teamed up to advance the treatment of adrenocortical carcinoma (ACC). The collaboration will support the Phase II clinical trial of Cytovation’s innovative therapy, CY-101.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-02T15:00:00
Sponsored by Danaher Life Sciences
2026-08-17T14:16:00
Contributor Dr Rab Prinjha, Drug Target Review
2026-03-11T14:00:00
Sponsored by Merck
2023-11-20T13:43:43
Sponsored by Merck
2024-01-10T08:56:17
Sponsored by Leica Microsystems
2026-09-30T13:00:00
Sponsored by Sartorius
Site powered by Webvision Cloud